WITTEN, Germany, April 16, 2012 /PRNewswire/ --
Subsequent to the granting of the CE mark authorizing production, distribution and sales in the member countries of the European Union, and after fifteen months of intensive strategic and operational preparation, global licensee SastoMed GmbH has initiated sales of Granulox today on the official approval of the first batch of products. Granulox, a spray aiming at improved healing of chronic wounds, is based on a patent by SanguiBioTech GmbH. It currently is the only therapeutic which can help to soothe the problem of hypoxia i.e. the lack of oxygen supply to chronic wounds. Indications as granted by the CE mark include diabetic foot, leg ulcer and decubitus ulcer.
"It is worth noticing", SastoMed Managing Director Michael Sander emphasized, "that thanks to our highly focused approach and diligent professional work we managed to obtain the CE mark ahead of our 2010 schedule but are fully prepared now for a head start into actual commercialization. This was our goal from the beginning and this first part of the mission was fully accomplished."
According to information provided by the joint venture company, SastoMed GmbH over the past months hired and trained a sales team of experienced wound management experts who will now take care of the German market. They will be supported by additional sales representatives. The sales team is focused on Granulox exclusively. In the course of premarketing activities multiple contacts among hospitals, wound ambulances and wound care practitioners have already been made aware of the advantages of Granulox. Based on the reaction by numerous experts, SastoMed, therefore, is pursuing ambitious sales targets and expects to having gained a 10% share of the market for modern wound treatment by the end of 2013.
The detailed marketing plan for the current year includes advertisement campaigns in specialized trade media, noticeable presence at key wound management conferences, congresses and medical trade fairs including booths, hosting of workshops and round table sessions as well as lectures and presentations, both in Germany and on an international level. Negotiations are underway with potential distributors in key European countries, SastoMed confirmed.
SastoMed also indicated that production capacity was contractually secured to meet demand beyond the current ambitious sales targets. Additional market assumptions and revenue expectations are to be disclosed at some later point in time after the launch phase of the sales initiatives.
SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc. (http://www.otcmarkets.com: SGBI)
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information please contact:
|SOURCE Sangui Bio Tech International Inc.|
Copyright©2010 PR Newswire.
All rights reserved